Replimune Group (NASDAQ:REPL) Stock Price Up 9.5% - What's Next?

Replimune Group, Inc. (NASDAQ:REPL - Get Free Report)'s stock price was up 9.5% during trading on Thursday . The company traded as high as $13.56 and last traded at $13.26. Approximately 518,051 shares traded hands during mid-day trading, a decline of 50% from the average daily volume of 1,040,285 shares. The stock had previously closed at $12.11.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on REPL. JPMorgan Chase & Co. upped their target price on shares of Replimune Group from $14.00 to $17.00 and gave the company an "overweight" rating in a research report on Tuesday, September 24th. Jefferies Financial Group raised their price objective on Replimune Group from $16.00 to $19.00 and gave the company a "buy" rating in a research note on Wednesday, December 4th. HC Wainwright reaffirmed a "buy" rating and issued a $17.00 price objective on shares of Replimune Group in a research note on Friday, November 22nd. Finally, BMO Capital Markets boosted their target price on Replimune Group from $14.00 to $18.00 and gave the company an "outperform" rating in a research report on Friday, November 22nd. Seven analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, Replimune Group presently has an average rating of "Buy" and an average price target of $17.29.

Replimune Group Trading Up 3.7 %

The company has a debt-to-equity ratio of 0.18, a quick ratio of 10.11 and a current ratio of 10.11. The stock has a fifty day moving average of $12.43 and a 200-day moving average of $10.98. The company has a market cap of $859.32 million, a PE ratio of -4.12 and a beta of 1.26.

Replimune Group (NASDAQ:REPL - Get Free Report) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.68) EPS for the quarter, topping analysts' consensus estimates of ($0.75) by $0.07. Sell-side analysts anticipate that Replimune Group, Inc. will post -2.91 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, CEO Sushil Patel sold 10,000 shares of the company's stock in a transaction dated Monday, December 16th. The shares were sold at an average price of $12.42, for a total value of $124,200.00. Following the completion of the sale, the chief executive officer now directly owns 202,014 shares of the company's stock, valued at $2,509,013.88. This represents a 4.72 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Konstantinos Xynos sold 7,246 shares of the stock in a transaction dated Monday, November 18th. The stock was sold at an average price of $10.78, for a total transaction of $78,111.88. Following the transaction, the insider now owns 109,885 shares in the company, valued at approximately $1,184,560.30. The trade was a 6.19 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 8.80% of the company's stock.

Institutional Investors Weigh In On Replimune Group

Hedge funds have recently modified their holdings of the business. Point72 DIFC Ltd purchased a new position in Replimune Group during the second quarter valued at approximately $57,000. Erste Asset Management GmbH bought a new position in shares of Replimune Group in the 3rd quarter worth $133,000. Arizona State Retirement System bought a new position in shares of Replimune Group in the 2nd quarter worth $108,000. China Universal Asset Management Co. Ltd. lifted its stake in shares of Replimune Group by 82.1% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 13,140 shares of the company's stock worth $144,000 after purchasing an additional 5,926 shares during the last quarter. Finally, Quest Partners LLC boosted its position in Replimune Group by 30.4% during the second quarter. Quest Partners LLC now owns 13,510 shares of the company's stock valued at $122,000 after purchasing an additional 3,150 shares in the last quarter. Hedge funds and other institutional investors own 92.53% of the company's stock.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.